Australia's most trusted
source of pharma news
Saturday, 14 December 2024
Posted 27 June 2024 PM
The TGA has followed in the footsteps of its overseas counterparts and added intestinal obstruction, including ileus, as a potential adverse effect to the Product Information (PI) of all GLP-1 receptor agonists (RAs) available in Australia.
Drugs impacted include Eli Lilly's Trulicty and Mounjaro, Novo Nordisk's semaglutide franchise, Ozempic, Wegovy, and Rybelsus along with its liraglutide-containing meds Saxenda, Victoza, and Xultophy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.